Novel application of eye medicine wrapped with erythrocyte membrane

A technology of red blood cell membranes and uses, which is applied in the field of preparation of ophthalmic preparations, can solve the problems of inconvenient use, etc., and achieve the effects of prolonging residence time, reducing systemic side effects, and improving bioavailability

Active Publication Date: 2014-02-05
GUANGZHOU KANGRUI BIOLOGICAL PHARMA TECH CO LTD
View PDF1 Cites 20 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] It can be seen that the above-mentioned drugs all need daily medication, which is not convenient enough for patients who need long-term medication.
Among the currently known sustained-release preparations, the longest drug action time can only last about 10 days

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel application of eye medicine wrapped with erythrocyte membrane
  • Novel application of eye medicine wrapped with erythrocyte membrane
  • Novel application of eye medicine wrapped with erythrocyte membrane

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Latanoprost-PCL Nanoparticles Wrapped in Erythrocyte Membrane in Example 1

[0031] Preparation of Latanoprost-Polycaprolactone (PCL) Nanoparticles by Emulsification

[0032] The specific method is: 440ug of latanoprost is dissolved in chloroform containing 4 mg of PCL ethanol solution. The mixture was sonicated and emulsified in 2 mL of water containing 0.25% (wt / wt) polyvinyl alcohol (PVA). After evaporating overnight in an organic solvent, the residue was washed in an Amicon 100k MWCO filter to remove PVA to obtain PCL nanoparticles. The size and dispersibility of the PCL particles were detected by a dynamic light scattering instrument.

[0033] Mix the red blood cell membrane with the above-mentioned prepared nanoparticles, and then extrude the mixture through a 400-nanometer porous membrane, and the resulting particles are latanoprost-PCL nanoparticles wrapped in red blood cell membranes, with an average diameter of 350 nanometers (See the transmission electron m...

Embodiment 2

[0035] Example 2 Latanoprost-PLGA nanoparticles wrapped in erythrocyte membrane

[0036] Preparation of Latanoprost-Polycaprolactone (PLGA) Nanoparticles by Emulsification

[0037] The specific method is:

[0038] First, the PLGA polymer was dissolved in acetone at a concentration of 1 mg / ml, and latanoprost was dissolved in the PLGA solution at 1 mM, and then 1 ml of the solution was added dropwise to 3 ml of water, and the resulting mixture was exposed to air and stirred for 2 hours After centrifugation or filtration, latanoprost PLGA nanoparticles can be obtained.

[0039] The erythrocyte membrane is mixed with the above-prepared nanoparticles, and then the mixture is extruded through a 400-nanometer porous membrane, and the resulting particles are latanoprost-PLGA nanoparticles wrapped in the erythrocyte membrane.

[0040] The beneficial effects of the present invention will be specifically described below through test examples.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of an eye medicine wrapped with an erythrocyte membrane in preparation of an eye preparation, and also provides the eye preparation. The preparation is in a form of biodegradable nano particles wrapped with the erythrocyte membrane. The preparation has the advantages that the shortcomings of the traditional eye drops that partial removal is quickly realized, the bioavailability is low, the eye drops are absorbed by the whole body, and the side effect is difficult to avoid, are overcome; the time of the medicine standing in eyes is obviously prolonged; the controlled-released administration of the medicine is realized. Therefore, the bioavailability of the medicine is improved, the side effect on the whole body is reduced, and a new hope is brought to clinical ophthalmology on treatment of intraocular diseases.

Description

technical field [0001] The invention relates to the application of ophthalmic medicine encapsulated by erythrocyte membrane in preparation of ophthalmic preparation. Background technique [0002] Latanoprost, a novel phenyl-substituted propyl ester prostaglandin F2a, is a selective F2a receptor agonist. Latanoprost is hydrolyzed into free acid in the cornea, and this free acid diffuses out from the cornea and enters the atrium, and reaches the peak blood level in about 2 hours. After 3 to 4 hours, the intraocular pressure begins to drop, and reaches the maximum drop in 8 to 12 hours. It has a good effect of lowering the intraocular pressure and can maintain the intraocular pressure for 24 hours without increasing the intraocular pressure. Eye drops are needed once a day. [0003] Bimatoprost is also used to reduce intraocular pressure in patients with open-angle glaucoma and ocular hypertension who cannot tolerate or are not sensitive enough to other intraocular pressure-lo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/5575A61K47/46B82Y5/00A61P27/02A61P27/06
Inventor 张康
Owner GUANGZHOU KANGRUI BIOLOGICAL PHARMA TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap